stockrow
Friday 6 November 2026
Export ONC’s income statement to Excel — free account
BeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
406.26
19.01
+4.91%
Follow ONC
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 3 | 2 | 4 | 6 | 3 | 3 | 4 | 7 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.40 |
P/S ratio |
167.75 | 17.64 | 39.23 | 23.25 | 69.83 | 21.37 | 16.51 | 7.51 | 5.10 | 6.20 |
Altman Z-Score |
9.93 | 7.11 | 8.74 | 6.67 | 6.50 | 5.87 | 5.26 | 3.29 | 3.16 | 5.25 |
Altman Z″-Score (non-manufacturers) |
8.64 | 5.11 | 5.09 | (2.83) | 2.84 | 4.23 | 0.65 | (1.53) | (2.06) | 1.78 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.95 |
P/Operating CF |
(36.88) | 44.93 | (40.11) | (37.26) | (64.90) | (49.50) | (73.46) | (83.36) | 258.75 | 79.39 |
Beneish M-Score |
— | — | (2.55) | (2.11) | (3.12) | 0.94 | (3.24) | (1.51) | (2.15) | (2.73) |
P/B ratio |
2.73 | 6.16 | 4.43 | 10.17 | 5.57 | 4.10 | 5.33 | 5.22 | 5.84 | 7.60 |
Price to Tangible BV |
2.73 | 6.34 | 4.57 | 10.24 | 5.58 | 4.13 | 5.38 | 5.31 | 5.93 | 7.71 |
EV/Sales |
106.69 | 14.82 | 31.17 | 21.54 | 56.50 | 16.30 | 13.68 | 6.44 | 4.54 | 5.59 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50.74 |
EV/Operating CF |
(6.85) | 277.55 | (11.28) | (12.29) | (13.60) | (14.76) | (12.95) | (13.68) | (123.13) | 26.50 |
EV/FCF |
(5.43) | (76.98) | (9.40) | (10.97) | (12.45) | (11.94) | (10.38) | (8.92) | (27.14) | 32.41 |
Quick Ratio |
10.50 | 5.78 | 7.45 | 3.40 | 4.38 | 4.44 | 3.21 | 1.95 | 1.49 | 2.96 |
Current Ratio |
10.68 | 6.09 | 7.89 | 3.78 | 4.61 | 4.76 | 3.55 | 2.32 | 1.80 | 3.41 |
Net Debt/EBITDA |
3.05 | 7.18 | 2.30 | 0.78 | 2.53 | 4.29 | 2.32 | 2.66 | 6.21 | (6.09) |
Debt/Assets |
4.26% | 15.74% | 8.82% | 15.60% | 9.51% | 7.63% | 8.44% | 3.40% | 2.81% | 11.75% |
Debt/Equity |
0.05 | 0.24 | 0.11 | 0.26 | 0.14 | 0.11 | 0.12 | 0.06 | 0.05 | 0.22 |
Asset Turnover |
0.00 | 0.33 | 0.12 | 0.22 | 0.09 | 0.17 | 0.19 | 0.40 | 0.65 | 0.76 |
Operating CF/Net income |
0.75 | (0.14) | 0.81 | 0.79 | 0.80 | 0.89 | 0.75 | 1.31 | 0.22 | 3.93 |
Capex/Depreciation |
(12.31) | (12.34) | (10.51) | (4.81) | (3.70) | (6.59) | (4.91) | (6.63) | (2.90) | (1.45) |
Interest Coverage |
305.64 | — | (50.70) | (103.85) | 829.67 | (106.88) | (24.03) | — | (26.06) | 7.68 |
| (94.94%) | (17.95%) | (55.28%) | (69.45%) | (65.88%) | (29.15%) | (38.11%) | (22.26%) | (18.77%) | 7.46% | |
| (45.63%) | (12.82%) | (40.88%) | (49.13%) | (44.28%) | (20.63%) | (26.87%) | (14.47%) | (11.00%) | 4.07% | |
ROIC |
(3,627.29%) | (538.37%) | (282.66%) | (243.08%) | 0.00% | (541.89%) | (289.43%) | (134.04%) | (40.76%) | 36.03% |
Return on Tangible Assets |
(32.63%) | (11.27%) | (36.33%) | (85.87%) | (37.63%) | (22.08%) | (43.71%) | (23.72%) | (19.22%) | 4.75% |
Average Days of Receivables |
0.00 | 45.06 | 75.60 | 60.42 | 71.38 | 149.91 | 44.64 | 53.15 | 64.78 | 59.10 |
Research and Development Expense of Revenue |
9,161.96% | 112.85% | 342.55% | 216.56% | 419.22% | 124.06% | 115.86% | 72.34% | 51.26% | 40.16% |
Selling, General and Administrative Expense of Revenue |
1,878.22% | 26.26% | 98.57% | 90.67% | 194.31% | 84.17% | 90.25% | 61.33% | 48.06% | 38.96% |
Intangible Assets out of Total Assets |
0.00 | 0.02 | 0.02 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
992.99% | 17.98% | 43.95% | 31.33% | 59.40% | 20.46% | 21.41% | 14.95% | 11.59% | 9.56% |
Graham Net Nets |
0.33 | 0.13 | 0.19 | 0.05 | 0.15 | 0.21 | 0.14 | 0.10 | 0.07 | 0.07 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.46 |
Earnings Yield |
(12.33%) | (2.17%) | (8.56%) | (9.50%) | (7.36%) | (5.58%) | (8.60%) | (4.77%) | (3.32%) | 0.86% |
Free Cash Flow Yield |
(11.72%) | (1.09%) | (8.45%) | (8.45%) | (6.50%) | (6.39%) | (7.98%) | (9.60%) | (3.28%) | 2.78% |
Revenue per Share |
0.03 | 5.71 | 3.58 | 7.13 | 3.70 | 12.68 | 13.73 | 23.55 | 36.19 | 48.99 |
Operating CF per Share |
(2.88) | 0.31 | (9.88) | (12.49) | (15.38) | (14.00) | (14.51) | (11.09) | (1.34) | 10.34 |
Capex per Share |
(0.76) | (1.41) | (1.97) | (1.49) | (1.41) | (3.30) | (3.16) | (5.57) | (4.72) | (1.89) |
Free Cash Flow per Share |
(3.64) | (1.10) | (11.85) | (13.99) | (16.78) | (17.30) | (17.67) | (16.66) | (6.06) | 8.45 |
Cash per Share |
11.86 | 20.04 | 32.39 | 16.37 | 55.72 | 71.33 | 43.97 | 30.39 | 24.95 | 41.70 |
Shareholders Equity per Share |
11.37 | 16.38 | 31.63 | 16.29 | 46.35 | 66.09 | 42.50 | 33.89 | 31.65 | 39.99 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.37 | 16.38 | 31.63 | 16.29 | 46.35 | 66.09 | 42.50 | 33.89 | 31.65 | 39.99 |
Free Cash Flow |
(113.01) | (45.98) | (656.85) | (839.88) | (1,400.97) | (1,605.07) | (1,822.05) | (1,738.71) | (637.97) | 921.74 |
Working Capital |
339.34 | 763.51 | 1,697.39 | 862.38 | 3,885.49 | 6,014.33 | 3,738.55 | 2,393.30 | 1,776.69 | 4,404.76 |
Capital Expenditures |
(23.50) | (58.73) | (109.13) | (89.61) | (117.51) | (306.35) | (325.43) | (581.26) | (497.34) | (205.84) |
Net Current Asset Value |
321.49 | 551.25 | 1,447.81 | 538.76 | 3,229.18 | 5,210.92 | 3,211.14 | 1,935.47 | 1,402.91 | 2,406.21 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.82 |
Capex to Sales |
21.96 | 0.25 | 0.55 | 0.21 | 0.38 | 0.26 | 0.23 | 0.24 | 0.13 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.10 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.07 | 0.08 | 0.07 | 0.08 | 0.09 | 0.08 | 0.08 | 0.07 | 0.11 | 0.09 |
Cash ROIC |
(15.31%) | (2.73%) | (17.53%) | (37.95%) | (15.48%) | (11.98%) | (19.27%) | (25.17%) | (10.41%) | 9.34% |
Accounts Receivable Turnover |
0.00 | 5.80 | 5.62 | 7.65 | 4.71 | 4.33 | 4.32 | 9.26 | 7.37 | 6.93 |
Accounts Payable Turnover |
0.00 | 0.12 | 0.31 | 0.60 | 0.40 | 0.67 | 1.03 | 1.25 | 1.65 | 1.51 |
Inventory Turnover |
— | 0.37 | 2.11 | 3.18 | 1.20 | 0.99 | 1.09 | 1.09 | 1.30 | 1.21 |
Average Days of Payables |
0.00 | 5,120.49 | 1,440.46 | 628.01 | 1,198.24 | 580.79 | 375.58 | 302.74 | 248.82 | 261.54 |
Days of Inventory on Hand |
— | 802.06 | 206.53 | 146.39 | 461.27 | 537.02 | 359.74 | 399.78 | 304.11 | 332.07 |
Average Receivables |
— | 41.10 | 35.24 | 55.97 | 65.64 | 271.76 | 328.14 | 265.60 | 517.15 | 770.68 |
Average Payables |
10.47 | 40.87 | 91.53 | 117.89 | 177.22 | 247.18 | 278.59 | 304.95 | 360.05 | 442.02 |
Average Inventory |
— | 13.55 | 13.59 | 22.40 | 58.92 | 165.96 | 262.49 | 349.23 | 455.55 | 551.61 |
Average Assets |
261.29 | 726.15 | 1,648.08 | 1,930.99 | 3,606.52 | 7,068.14 | 7,457.41 | 6,092.28 | 5,863.09 | 7,054.74 |
Average Common Equity |
125.57 | 518.57 | 1,218.94 | 1,366.00 | 2,423.80 | 5,000.90 | 5,257.96 | 3,960.34 | 3,434.77 | 3,846.71 |
Columns are period end dates · fundamentals updated 5 Nov 2026